Sector News

Endo looks to acquire Auxilium in $2.2 billion deal

September 17, 2014
Life sciences
Endo International is looking to acquire Auxilium Pharmaceuticals in a deal worth $2.2 billion.
 
Its offer of $28.10 per share in cash and stock represents a premium of 31% to Auxilium’s closing price yesterday (September 16), though the latter’s shares shot up 37% to over $29.50 in after-hours trading.
 
The chief attraction of Endo is Xiaflex (collagenase clostridium histolyticum) which is approved in the USA for Dupuytren’s contracture, which affects the connective tissue beneath the skin in the palm of the hand, and Peyronie’s disease, which causes a bothersome curvature of the penis during sex. It has a total of 12 Food and Drug Administration-approved products in urology, orthopaedic and other areas, including Stendra (avanafil), an oral erectile dysfunction drug, which are “natural complements to the men’s health and pain products in Endo’s pharmaceuticals portfolio”, the latter firm claims.
 
Rajiv De Silva, Endo chief executive, said the proposal would provide Auxilium shareholders “a substantial premium and immediate cash value for their investment…as well as the opportunity to participate in the upside potential of a leading global specialty healthcare company”. He added that Endo “stands ready to engage immediately with Auxilium, complete our confirmatory diligence, negotiate a definitive agreement and complete this exciting transaction”.
 
Auxilium is saying nothing for the moment about the Endo bid but just a week ago announced it was reducing its headcount by 30% in a bid to reduce operating expenses by more than $75 million. It is also in the process of acquiring Canadian biotech QLT.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach